The FDA's clearance of Context Therapeutics' IND application for a Phase 1 clinical trial is a critical regulatory milestone that typically leads to positive investor sentiment. This approval suggests the company is advancing in its clinical development pathway, which can be seen as a positive indicator of its future prospects and potential for growth. As a result, this news is likely to have a favorable impact on the company's stock price in the short term, as it reflects progress in the development of its product pipeline.